Literature DB >> 24365372

Chronic myeloproliferative diseases.

João Forjaz de Lacerda1, Sofia N Oliveira2, José M Ferro3.   

Abstract

The chronic myeloproliferative disorders are a group of diseases in which there is an increased proliferation of one or more subtypes of myeloid cells; they include essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). In ET and PV the main neurologic manifestations are headaches, dizziness and macro- and microvascular, both venous and arterial, thrombosis and intracranial hemorrhages. Paresthesias and chorea also occur in PV. In PMF neurologic complications are very rare and consist predominantly of spinal cord compression by extramedullary hematopoiesis tissue.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Myeloproliferative disorder; myelofibrosis; polycythemia; thombocythemia; thrombosis

Mesh:

Substances:

Year:  2014        PMID: 24365372     DOI: 10.1016/B978-0-7020-4087-0.00072-3

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  3 in total

1.  Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis.

Authors:  Kuan-Hung Lin; Ya-Hsuan Ho; Jui-Chung Chiang; Meng-Wei Li; Shi-Hung Lin; Wei-Min Chen; Chi-Ling Chiang; Yu-Nung Lin; Ya-Jan Yang; Chiung-Nien Chen; Jenher Lu; Chang-Jen Huang; Gabor Tigyi; Chao-Ling Yao; Hsinyu Lee
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

Review 2.  Review of Hereditary and Acquired Rare Choreas.

Authors:  Daniel Martinez-Ramirez; Ruth H Walker; Mayela Rodríguez-Violante; Emilia M Gatto
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-08-06

3.  Rapidly progressive cognitive impairment: an unusual presentation of cerebral venous thrombosis caused by JAK2 V617F-positive primary myelofibrosis: A case report.

Authors:  Chongyao Jin; Jiali Pu; Zhijian Zhou; Xia Chen; Jimin Wu; Baorong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.